This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.

 

This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?
AASLD
Washington, D.C., USA
2022
Symposium

Date and time:

07.11.22 at 07:00-08:00 EST

Type:

Congress:
Speakers:

Opportunities to manage NASH: a hidden epidemic

How we screen, diagnose and manage NASH today – what the guidelines say
How NITs are transforming the NASH management landscape
NASH medication score card and its potential future use

Voices of hope: what does the future look like for patients with NASH?

Manal Abdelmalek - Speaker

Manal Abdelmalek

NAFLD Clinical Research Program Division of Gastroenterology & Hepatology Mayo Clinic, Rochester, MN, USA


Dr Manal Abdelmalek is a Professor of Medicine, Director of the Hepatobiliary Interest Group and Non-alcoholic Fatty Liver Disease (NAFLD) Clinical Research Program at Mayo Clinic, Rochester, Minnesota, USA.

Her clinical and research area of interest is focused on NAFLD/NASH, associated risk factors for disease acquisition and progression, and the discovery of novel approaches to treatment. She has expertise in clinical-translational research, the design and conduct of clinical trials (investigator-initiated, industry sponsored and National Institutes of Health (NIH)-funded clinical studies evaluating new therapies and biomarkers for NAFLD and NASH) and is the lead Principal Investigator on several multicenter global studies. Dr Abdelmalek is a key opinion leader in the field of NASH therapeutics, a member of the Liver Forum, and advisor/consultant to many industries, the US Food and Drug Administration, and biomarker development companies in the area of diagnostics and therapeutics for NASH. Dr Abdelmalek is a Fellow of the American College of Physicians, American College of Gastroenterology and American Association for the Study of Liver Disease (where she is a member of the Global Outreach and Engagement Committee, and past member of the Clinical Research Committee). She is a steering committee member of the NIH Liver Cirrhosis Network and a former 16-year member of the NASH Clinical Research Network (NASH CRN). Dr Abdelmalek has published more than 200 manuscripts and currently serves as an Associate Editor of Hepatology, the official journal of the AASLD.  


Read full bio
Naim Alkhouri - Speaker

Naim Alkhouri

Arizona Liver Health, Phoenix, AZ, USA


Dr Naim Alkhouri is the Chief Medical Officer, Chief of Transplant Hepatology, and Director of the Fatty Liver Program at Arizona Liver Health in Phoenix, AZ, USA.

He has previously served as Director of the Metabolic Health Center at the Texas Liver Institute, San Antonio, TX, USA, and Associate Professor of Medicine and Pediatrics at the University of Texas Health, San Antonio, TX, USA. Dr Alkhouri completed his Gastroenterology and Transplant Hepatology training at the renowned Cleveland Clinic in Cleveland, OH, USA, where he was also appointed Assistant Professor of Medicine and Director of the Metabolic Liver Disease Clinic in the Digestive Disease and Surgery Institute.

Dr Alkhouri's special interests include nonalcoholic fatty liver disease (NAFLD), metabolic liver diseases, viral hepatitis, autoimmune hepatitis, alpha-1 antitrypsin deficiency and liver transplantation. He is a key opinion leader in the field of non-alcoholic steatohepatitis (NASH) therapeutics and an advisor/consultant to many pharmaceutical and biomarker development companies. He is Principal Investigator on several multicenter global NASH trials, and a member of the American Association for the Study of Liver Diseases (AASLD) NASH Special Interest Group.

Dr Alkhouri is an author of over 200 publications in journals including the New England Journal of Medicine, Lancet, JAMA, Gastroenterology, Hepatology and Journal of Hepatology. Among many research awards, Dr Alkhouri received the American College of Gastroenterology Junior Faculty Development Award to study the analysis of breath volatile organic compounds to diagnose nonalcoholic fatty liver disease. 


Read full bio